VACH Overview

Class Action Firm Recognition: Monteverde & Associates PC, led by attorney Juan Monteverde, is recognized as a Top 50 Firm in the 2024 ISS Securities Class Action Services Report and has successfully recovered millions for shareholders.

PB Bankshares Investigation: The firm is investigating PB Bankshares Inc. regarding its sale to Norwood Financial Corp., where shareholders can choose between shares or cash, with a shareholder vote scheduled for December 10, 2025.

Other Mergers and Acquisitions: The firm is also involved in cases related to Voyager Acquisition Corp.'s merger with Veraxa Biotech AG, Lifeloc Technologies' merger with Electronic Systems Technology, and Semler Scientific's sale to Strive, Inc.

Contact Information: Shareholders with concerns or seeking more information can contact Juan Monteverde via email or phone, with services offered at no cost or obligation.

Business Combination Announcement: VERAXA Biotech AG and Voyager Acquisition Corp. have filed a registration statement with the SEC regarding their proposed business combination, which is expected to close in Q4 2025, valuing VERAXA at approximately $1.64 billion.

Transaction Details: The merger will result in existing VERAXA shareholders receiving shares in the combined company without cash proceeds, while VERAXA anticipates access to around $253 million in cash held by Voyager, subject to shareholder approvals and customary closing conditions.

Class Action Firm Overview: Monteverde & Associates PC, led by attorney Juan Monteverde, is recognized as a top firm for recovering millions for shareholders and is currently investigating Voyager Acquisition Corp.'s merger with Veraxa Biotech AG.

Legal Services Offered: The firm emphasizes its successful track record in class action lawsuits and invites shareholders to contact them for free consultations regarding their concerns about the merger.

Company Overview: VERAXA Biotech AG is set to showcase its innovative cancer therapies, particularly the Bi-targeted Tumor-Associated Cytotoxicity (BiTAC) platform, at the ASCO and BIO conventions while preparing for a NASDAQ listing through a merger with Voyager Acquisition Corp.

Event Participation: The company will attend the ASCO Annual Meeting from May 30 to June 3, 2025, and the BIO International Convention from June 16 to June 19, 2025, where it aims to engage potential investors and partners.

VERAXA Biotech AG Announcement: VERAXA, a company focused on cancer therapies, will attend the ASCO Annual Meeting and BIO International Convention to showcase its Bi-targeted Tumor-Associated Cytotoxicity (BiTAC) platform and discuss growth plans as it prepares for a NASDAQ listing following a business combination with Voyager Acquisition Corp.

Business Combination Details: The merger with Voyager Acquisition Corp. aims to enhance VERAXA's capabilities in developing innovative oncology treatments, with both companies emphasizing their commitment to revolutionizing the healthcare sector through this partnership.